Boston Partners Reduces Stake in Augmedix, Inc. (NASDAQ:AUGX)

Boston Partners trimmed its stake in shares of Augmedix, Inc. (NASDAQ:AUGXFree Report) by 49.4% during the 3rd quarter, Holdings reports. The fund owned 62,879 shares of the company’s stock after selling 61,445 shares during the quarter. Boston Partners’ holdings in Augmedix were worth $324,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Barclays PLC bought a new position in Augmedix during the 3rd quarter worth approximately $115,000. Jump Financial LLC grew its position in Augmedix by 173.1% during the 3rd quarter. Jump Financial LLC now owns 37,408 shares of the company’s stock worth $193,000 after acquiring an additional 23,708 shares during the last quarter. Tucker Asset Management LLC bought a new position in Augmedix during the 2nd quarter worth approximately $172,000. Portside Wealth Group LLC bought a new position in Augmedix during the 2nd quarter worth approximately $286,000. Finally, Taylor Frigon Capital Management LLC bought a new position in Augmedix during the 3rd quarter worth approximately $438,000. 71.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Evercore ISI began coverage on Augmedix in a research report on Friday, December 15th. They issued an “inline” rating and a $6.00 price objective on the stock.

View Our Latest Analysis on AUGX

Augmedix Stock Performance

Shares of AUGX stock opened at $4.32 on Friday. The company has a market cap of $178.68 million, a price-to-earnings ratio of -8.47 and a beta of -0.14. Augmedix, Inc. has a fifty-two week low of $1.34 and a fifty-two week high of $6.25. The stock has a 50 day simple moving average of $5.28. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 17.18.

Augmedix (NASDAQ:AUGXGet Free Report) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The firm had revenue of $11.77 million for the quarter, compared to analyst estimates of $11.41 million. Augmedix had a negative return on equity of 2,702.83% and a negative net margin of 49.55%.

Insider Activity

In other news, CFO Paul Ginocchio bought 10,000 shares of the stock in a transaction dated Wednesday, November 22nd. The stock was bought at an average price of $4.85 per share, for a total transaction of $48,500.00. Following the purchase, the chief financial officer now directly owns 128,000 shares in the company, valued at approximately $620,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.97% of the stock is currently owned by company insiders.

About Augmedix

(Free Report)

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Notes that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, a self-service mobile software application.

Featured Articles

Want to see what other hedge funds are holding AUGX? Visit to get the latest 13F filings and insider trades for Augmedix, Inc. (NASDAQ:AUGXFree Report).

Institutional Ownership by Quarter for Augmedix (NASDAQ:AUGX)

Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with's FREE daily email newsletter.